Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Arcutis Biotherapeutics, Inc. - Common stock (ARQT)
Company Research
Source: GlobeNewswire
WESTLAKE VILLAGE, Calif., March 05, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today reported the grant of an aggregate of 27,000 restricted stock units of Arcutis’ common stock to three newly hired employees. These awards were approved by the Compensation Committee of Arcutis’ Board of Directors and granted under the Arcutis Biotherapeutics, Inc. 2022 Inducement Plan, with a grant date of March 3, 2025, as an inducement material to the new employees entering into employment with Arcutis, in accordance with Nasdaq Listing Rule 5635(c)(4). The restricted stock units vest over four years,
Read more
Impact Snapshot
Event Time:
ARQT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ARQT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ARQT alerts
High impacting Arcutis Biotherapeutics, Inc. - Common stock news events
Weekly update
A roundup of the hottest topics
ARQT
News
- ZORYVE® Cream 0.15% Approved by Health Canada for the Treatment of Mild to Moderate Atopic Dermatitis in Adults and Children as Young as Six Years of Age [Yahoo! Finance]Yahoo! Finance
- Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) had its price target raised by analysts at Jefferies Financial Group Inc. from $16.00 to $19.00. They now have a "buy" rating on the stock.MarketBeat
- Arcutis to Highlight Data from Phase 3 Trials for Scalp and Body Psoriasis and Atopic Dermatitis at the 83rd American Academy of Dermatology MeetingGlobeNewswire
- Arcutis Biotherapeutics, Inc. (ARQT) Just Overtook the 50-Day Moving Average [Yahoo! Finance]Yahoo! Finance
- Wall Street Analysts See a 48.36% Upside in Arcutis Biotherapeutics (ARQT): Can the Stock Really Move This High? [Yahoo! Finance]Yahoo! Finance
ARQT
Earnings
- 2/25/25 - Beat
ARQT
Sec Filings
- 3/17/25 - Form 4
- 3/14/25 - Form 144
- 3/13/25 - Form 144
- ARQT's page on the SEC website